<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1004233519
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZEMPLAR 2 mcg Capsule
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PARICALCITOL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        852.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="CATALENT PHARMA SOLUTIONS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            CATALENT PHARMA SOLUTIONS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 392]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AL-KAMAL IMPORT OFFICE CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Abbvie Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A11CC07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Zemplar contains the active substance paricalcitol, which is a synthetic form of active vitamin D.</p><p><strong>&nbsp;</strong></p><p>Active vitamin D is required for the normal functioning of many tissues in the body, including the parathyroid gland and bones.&nbsp; In people who have normal kidney function, this active form of vitamin D is naturally produced by the kidneys, but in kidney failure the production of active vitamin D is markedly reduced. Zemplar therefore provides a source of active vitamin D, when the body cannot produce enough and helps to prevent the consequences of low levels of active vitamin D, in patients with kidney disease (Stages 3, 4 and 5) namely high levels of parathyroid hormone which can cause bone problems.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Zemplar</strong></p><p>- &nbsp;if you are allergic to paricalcitol or any of the other ingredients of this medicine (listed in section 6).</p><p>- &nbsp;if you have very high levels of calcium or vitamin D in your blood.</p><p>&nbsp;</p><p>Your doctor will be able to tell you if these conditions apply to you</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p><strong>&nbsp;</strong></p><p>Talk to your doctor or pharmacist before taking Zemplar..</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; before the treatment begins, it is important to limit the amount of phosphorus in your diet.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phosphate-binding medicines may be needed to control phosphorus levels. If you are taking calcium-based phosphate binders, the doctor may need to adjust your dose.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your doctor will need to do blood tests to monitor your treatment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in some patients with chronic kidney disease stages 3 and 4, an increase in the blood levels of a substance called creatinine has been observed.&nbsp; However, this increase does not reflect a reduction in renal function.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Zemplar</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>Some medicines may affect the action of this medicine or may increase the likelihood of side effects. It is particularly important to tell your doctor if you are taking any of the following medicines:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to treat fungal infections such as candida or thrush (for example ketoconazole);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to treat heart problems or high blood pressure (for example digoxin, diuretics or water pills);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; that contain a source of phosphate (for example, medicines to lower calcium levels in the blood);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; that contain calcium or Vitamin D, including supplements and multivitamins that can be bought without a prescription;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; that contain magnesium or aluminium (for example some types of indigestion medicines (antacids) and phosphate-binders);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to treat elevated cholesterol levels (for example cholestyramine).</p><p>&nbsp;</p><p><strong>Zemplar with food and drink</strong></p><p>Zemplar may be taken with or without food.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. There is no adequate data on the use of paricalcitol in pregnant women.&nbsp; Potential risk in human use is not known, therefore paricalcitol should not be used unless clearly necessary.</p><p>&nbsp;</p><p>It is not known if paricalcitol passes into human breast milk. Tell your doctor before breast-feeding while taking Zemplar.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p>Zemplar should not affect your ability to drive or use machines.</p><p>&nbsp;</p><p><strong>&nbsp;Zemplar contains ethanol (alcohol)</strong></p><p>&nbsp;</p><p>This medicine contains 1.42 mg of alcohol (ethanol) in each 2 microgram capsule. The small amount of alcohol in this medicine will not have any noticeable effects.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.&nbsp;</p><p>&nbsp;</p><p>Chronic Kidney Disease Stages 3 and 4</p><p>The usual dose is one capsule every day, or every other day, up to three times a week.&nbsp; Your doctor will use the results of your laboratory tests to decide the correct dose for you. Once Zemplar is started, the dose is likely to need adjusting, depending on how you respond to treatment.&nbsp; Your doctor will help determine the correct dose of Zemplar for you.</p><p><strong><em>&nbsp;</em></strong></p><p>Chronic Kidney Disease Stage 5</p><p>The usual dose is one capsule every other day, up to three times a week.&nbsp; Your doctor will use the results of your laboratory tests to decide the correct dose for you.&nbsp; Once Zemplar is started, the dose is likely to need adjusting, depending on how you respond to treatment.&nbsp; Your doctor will help determine the correct dose of Zemplar for you.</p><p>&nbsp;</p><p><strong>Liver disease</strong></p><p>If you have mild to moderate liver disease, your dose will not need to be adjusted.&nbsp; However, there is no experience in patients with severe liver disease.</p><p>&nbsp;</p><p><strong>Renal transplant</strong></p><p>The usual dose is one capsule every day, or every other day, up to three times a week.&nbsp; Your doctor will use the results of your laboratory tests to decide the correct dose for you. Once Zemplar is started, the dose is likely to need adjusting, depending on how you respond to treatment.&nbsp; Your doctor will help determine the correct dose of Zemplar for you.</p><p>&nbsp;</p><p><strong>Use in children and adolescents</strong></p><p>There is no information on the use of Zemplar capsules in children.</p><p><strong>&nbsp;</strong></p><p><strong>Use in elderly</strong></p><p>There is a limited amount of experience of using Zemplar in patients aged 65 years or older.&nbsp; In general no overall differences in effectiveness or safety were seen between patients aged 65 years or older and younger patients.</p><p>&nbsp;</p><p><strong>If you take more Zemplar than you should</strong></p><p>Too much Zemplar can cause abnormally high levels of calcium in the blood, which can be harmful.&nbsp; Symptoms which can appear soon after taking too much Zemplar may include a feeling of weakness and/or drowsiness, headache, nausea (feeling sick) or vomiting (being sick), a dry mouth, constipation, pains in muscles or bones and a metallic taste in the mouth.</p><p>&nbsp;</p><p>Symptoms which can develop over a longer period of taking too much Zemplar include loss of appetite, drowsiness, weight loss, sore eyes, a runny nose, itchy skin, feeling hot and feverish, loss of sex drive and severe abdominal pain (due to an inflamed pancreas) and kidney stones.&nbsp; Your blood pressure may be affected and heart beat irregularities (palpitations) can occur.&nbsp; The results of blood and urine tests may show high cholesterol, urea, nitrogen and raised levels of liver enzymes. Zemplar may rarely cause mental changes including confusion, drowsiness, insomnia or nervousness.</p><p>&nbsp;</p><p>If you take too much Zemplar, or experience any of the above, seek medical advice immediately.</p><p>&nbsp;</p><p><strong>If you forget to take Zemplar</strong></p><p>If you forget to take a dose, take it as soon as your remember. However, if it is almost time for your next dose, do not take the dose that you have missed, simply continue to take Zemplar as previously directed (dose and time) by your doctor.</p><p>&nbsp;</p><p>Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop taking</strong><strong> Zemplar </strong></p><p>Unless your doctor tells you to stop your treatment, it is important to keep taking Zemplar as your doctor has directed.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Important: Tell your doctor immediately if you notice any of the following side effects:</strong></p><p>&nbsp;</p><p>Common (may affect up to 1 in 10 people) side effects seen in patients during use of paricalcitol capsules include increase in the blood levels of a substance called calcium, as well as the amount of calcium times the amount of another substance in the blood called phosphate (in patients with significant chronic kidney disease).</p><p>&nbsp;</p><p>Uncommon (may affect up to 1 in 100 people) side effects seen in patients during use of paricalcitol capsules include allergic reactions (such as shortness of breath wheezing, rash, itching, or swelling of the face and lips), decreased levels of parathyroid hormone, diarrhea, muscle cramps, nausea, dizziness, stomach discomfort or pain, vomiting, weakness, tired, rash, pneumonia, decreased appetite, increased levels of phosphorous, decreased levels of calcium, unusual taste in the mouth, irregular heartbeat, constipation, dry mouth, heartburn (reflux or indigestion), acne, itchy skin, hives, muscle pain, breast tenderness, not feeling well, swelling in the legs, pain, increased levels of creatinine, and changes in liver function tests.</p><p><strong>&nbsp;</strong></p><p>If you experience an allergic reaction, please contact your doctor immediately.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p><strong>&nbsp;</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p><p>&nbsp;</p><p>You can also report side effects (see details below).</p><p>&nbsp;</p><p>By reporting side affects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>To report any side effect(s):</p><p><strong>Saudi Arabia</strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: +966-11-205-7662</p><p>Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>Toll free phone: 8002490000</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p><p><strong>&nbsp;</strong></p><p><strong>Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Store ZEMPLAR Capsules below 25&deg;C (77&deg;F)</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and label after EXP. This expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Zemplar contains</strong></p><p><u>&nbsp;</u></p><p>The active substance is paricalcitol. Each soft capsule contains 2 micrograms of paricalcitol.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:&nbsp; medium chain triglycerides, ethanol, butylhydroxytoluene.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The capsule shell contains: gelatin, glycerol, water, titanium dioxide (E 171), iron oxide red (E 172) and iron oxide yellow (E 172).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The printing ink contains: propylene glycol, black iron oxide (E172), polyvinyl acetate phthalate, Macrogol 400, ammonium hydroxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Zemplar 2 micrograms capsules, is an oval, orange-brown soft capsule imprinted with ‘ZF’.
	
Each carton contains either 1 or 4 foil blister packs. Each blister contains 7 capsules. 
High-density polyethylene (HDPE) bottles closed with child-resistant polypropylene caps.  Each bottle contains 30 capsules. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder :</p><p>AbbVie Ltd,</p><p>&nbsp;Maidenhead, SL6 4UB</p><p>United Kingdom</p><p>&nbsp;</p><p>Manufacturer:</p><p>Catalent Pharma Solutions, LLC, St. Petersburg, United states</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	This leaflet was last revised in  June 2022.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي زمبلار على المادة الفعالة باريكالسيتول، وهي شكل تركيبي من الفيتامين د النشط.&nbsp;&nbsp;&nbsp;</p><p><strong>&nbsp;</strong></p><p dir="RTL">فيتامين د النشط ضروري من أجل الأداء الوظيفي الطبيعي للعديد من أنسجة الجسم، بما في ذلك الغدة الجار الدرقية والعظام.&nbsp; عند الأفراد الذين يتمتعون بوظيفة كلوية طبيعية، تنتج الكليتان هذا الشكل النشط من الفيتامين د بشكل طبيعي، ولكن في حالات الفشل الكلوي، فإن إنتاج الفيتامين د النشط يتراجع بشكل واضح. لذا يوفّر زمبلار مصدرا لفيتامين د النشط، عندما لا يتمكن الجسم من إنتاج ما يكفي منه ويساعد على الوقاية من عواقب المستويات المنخفضة من فيتامين د النشط، لدى المرضى المصابين بمرض كلوي (المراحل ٣، ٤ و٥) أي ارتفاع معدّلات هرمون الجار درقي الذي قد يسبب مشاكل في العظام.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول زمبلار</strong></p><p dir="RTL">- &nbsp;إذا كنت مصابا بالحساسية تجاه باريكالسيتول أو أي من مكونات هذا الدواء الأخرى (المذكورة في القسم ٦).</p><p dir="RTL">- &nbsp;إذا كنت مصابا بارتفاع معدّل الكالسيوم أو الفيتامين د في دمك.</p><p>&nbsp;</p><p dir="RTL">سيتمكن طبيبك من إخبارك إذا كانت هذه الحالات تنطبق عليك.</p><p>&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلاني قبل تناول زمبلار.</p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل البدء بالعلاج، من المهم أن تحدّد كمية الفُسفور في حميتك الغذائية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تحتاج لاستعمال الأدوية الرابطة للفُسفات من أجل التحكم بمعدلات الفُسفور. إذا كنت تتناول رابطات الفُسفات الكلسية الأساس، فقد يحتاج الطبيب إلى تعديل جرعتك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيحتاج الطبيب لإجراء اختبارات الدم لمراقبة علاجك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لوحظ ارتفاع في المعدلات الدموية لمادة تدعى الكرياتينين لدى بعض المرضى في المرحلتين الثالثة والرابعة من المرض الكلوي المزمن. على أي حال، لا يشير هذا الارتفاع إلى تراجع في الوظيفة الكلوية.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأدوية الأخرى وزمبلار</strong></p><p dir="RTL">أعلم طبيبك أو الصيدلاني إذا كنت تتناول حالياً، تناولت مؤخّراً، أو قد تتناول أي دواء آخر.&nbsp;&nbsp;</p><p>&nbsp;</p><p dir="RTL">قد تؤثر بعض الأدوية على عمل هذا الدواء أو قد تؤدي إلى زيادة إمكانية حدوث التأثيرات الجانبية. من المهم جدا ان تعلم طبيبك إذا كنت تتناول أيا من الادوية التالية:&nbsp;</p><p>&nbsp;</p><p dir="RTL">- الأدوية التي تستعمل لعلاج حالات العدوى الفطرية مثل داء المبيضات أو السلاق (مثل كيتوكونازول على سبيل المثال)؛</p><p dir="RTL">- الأدوية التي تستعمل لعلاج اضطرابات القلب مثل ارتفاع ضغط الدم (مثل الديجوكسين، الأدوية المدرّة أو أقراص الماء)؛</p><p dir="RTL">- الأدوية التي تحتوي على مصدر للفُسفات (مثل الأدوية التي تخفض معدلات الكالسيوم في الدم)؛</p><p dir="RTL">- الأدوية التي تحتوي على الكالسيوم أو الفيتامين د، بما في ذلك المكملات ومركبات الفيتامينات المتعددة التي يمكن شراؤها<br />&nbsp;&nbsp; دون وصفة طبية؛</p><p dir="RTL">- الأدوية التي تحتوي على المغنيزيوم أو الألمنيوم (مثل بعض أنواع أدوية عسر الهضم (مضادات الحموضة) ورابطات<br />&nbsp; الفُسفات)؛</p><p dir="RTL">- الأدوية التي تستعمل لعلاج معدلات الكوليسترول المرتفعة (مثل الكوليستيرامين على سبيل المثال).</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong><strong>زمبلار مع الطعام والشراب</strong></p><p dir="RTL">يمكن تناول زمبلار مع الطعام أو من دونه.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل، الإرضاع والخصوبة</strong></p><p dir="RTL">إذا كنت حاملا أو مرضعا، أو تعتقدين بأنك حامل أو تخططين للإنجاب، فاطلبي نصيحة طبيبك أو الصيدلاني قبل تناول هذا الدواء. &nbsp;&nbsp;&nbsp;لا تتوفر بيانات كافية عن استعمال باريكالسيتول لدى السيدات الحوامل. المخاطر التي قد تترتب على استعماله عند البشر ليست معروفة، لذا يجب الامتناع عن استعمال باريكالسيتول إلا في حال الضرورة القصوى.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">ليس من المعروف ما إذا كان باريكالسيتول ينتقل إلى حليب الثدي. أخبري طبيبك قبل الإرضاع إذا كنت تتلقين زمبلار.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>قيادة السيارات واستعمال الآليات</strong></p><p dir="RTL">من غير المفترض أن يؤثر زمبلار على قدرتك على القيادة أو استعمال الآليات.</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;يحتوي زمبلار على الإيثانول (الكحول)</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي هذا الدواء على 1.42 ملغم من الإيثانول (كحول) في كل كبسولة. هذه الكمية القليلة في هذا الدواء لن يكون لها أي تأثير يذكر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب استعمال هذا الدواء دوما ملتزما تماما بالطريقة التي أشار عليك بها طبيبك. اسأل طبيبك أو الصيدلاني إذا لم تكن متأكدا.&nbsp;</p><p>&nbsp;</p><p>المرحلتان الثالثة والرابعة من المرض الكلوي المزمن</p><p dir="RTL">يبلغ مقدار الجرعة العادية كبسولة واحدة كل يوم، أو كل يومين، بما لا يزيد عن ثلاث مرات أسبوعيا. سيعتمد طبيبك على نتائج فحوصاتك المخبرية ليقرر جرعة البدء الصحيحة المناسبة لك. بمجرد البدء بتناول زمبلار، من المرجح أن تحتاج الجرعة إلى تعديل، استنادا إلى تجاوبك مع العلاج. سيساعد طبيبك في تقرير جرعة زمبلار المناسبة لك.</p><p><strong><em>&nbsp;</em></strong></p><p>المرحلة الخامسة من المرض الكلوي المزمن</p><p dir="RTL">يبلغ مقدار الجرعة العادية كبسولة واحدة كل يومين، بما لا يزيد عن ثلاث مرات أسبوعيا. سيعتمد طبيبك على نتائج فحوصاتك المخبرية ليقرر جرعة البدء الصحيحة المناسبة لك. بمجرد البدء بتناول زمبلار، من المرجح أن تحتاج الجرعة إلى تعديل، استنادا إلى تجاوبك مع العلاج. سيساعد طبيبك في تقرير جرعة زمبلار المناسبة لك.</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>مرض الكبد </strong></p><p dir="RTL">إذا كنت مصابا بمرض الكبد الطفيف أو المعتدل الشدة، فلن تكون جرعتك بحاجة لتعديل.على أي حال، لا توجد خبرة بالنسبة للمرضى المصابين بمرض كبدي شديد.</p><p>&nbsp;</p><p dir="RTL"><strong>زرع الكلى</strong></p><p dir="RTL">يبلغ مقدار الجرعة العادية كبسولة واحدة كل يوم، أو كل يومين، بما لا يزيد عن ثلاث مرات أسبوعيا. سيعتمد طبيبك على نتائج فحوصاتك المخبرية ليقرر جرعة البدء الصحيحة المناسبة لك. بمجرد البدء بتناول زمبلار، من المرجح أن تحتاج الجرعة إلى تعديل، استنادا إلى تجاوبك مع العلاج. سيساعد طبيبك في تقرير جرعة زمبلار المناسبة لك.</p><p>&nbsp;</p><p dir="RTL"><strong>الاستعمال لدى الأطفال والمراهقين</strong></p><p dir="RTL">لا توجد معلومات عن استعمال كبسولات زمبلار عند الأطفال.&nbsp;</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong><u>الاستعمال عند المسنين</u></strong></p><p dir="RTL">هناك خبرة محدودة عن استعمال زمبلار عند المرضى الذين بلغوا ٦٥ سنة من العمر أو أكثر. بشكل عام، لم تشاهد اختلافات إجمالية في الفعالية أو الأمان بين المرضى الذين بلغوا ٦٥ سنة أو أكثر وبين المرضى الأصغر سنا.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا تناولت أكثر مما ينبغي من زمبلار</strong></p><p dir="RTL">قد تسبب الكميات الكبيرة من زمبلار معدلات مرتفعة جدا من الكالسيوم في الدم، وهذا ما قد يكون مؤذيا. قد تتضمن الأعراض التي قد تظهر سريعا بعد تناول كميات كبيرة جدا من زمبلار الشعور بالضعف و / أو الدوخة، الصداع، الغثيان (الشعور بحاجة للتقيؤ) أو التقيؤ، الفم الجافّ، الإمساك، آلام عضلية أو عظمية والشعور بطعم معدني في الفم.</p><p>&nbsp;</p><p dir="RTL">تتضمن الأعراض التي قد تظهر بعد فترة أطول من تناول كميات كبيرة جدا من زمبلار نقص الشهية، الدوخة، نقص الوزن، ألم العينين، سيلان الأنف، جلد حاكّ، الشعور بالدفء وارتفاع الحرارة، فقد الرغبة الجنسية وألم شديد في البطن (نتيجة لالتهاب البنكرياس) والحصيات الكلوية. قد يتأثر ضغط الدم لديك ومن الممكن أن تحدث اضطرابات في ضربات القلب (خفقان). قد تظهر نتائج الفحوصات على الدم والبول ارتفاع الكولسترول، البولة، النتروجين ومعدلات مرتفعة للخمائر الكبدية. في حالات نادرة قد يسبب زمبلار تغيرات ذهنية تتضمن الارتباك، النعاس، الأرق أو العصبية.</p><p>&nbsp;</p><p dir="RTL">إذا تناولت أكثر مما يينبغي من زمبلار، أو أصبت بأي من التأثييرات الجانبية المذكورة أعلاه، فاطلب مشورة طبية على الفور.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا نسيت أن تتناول زمبلار</strong></p><p dir="RTL">إذا نسيت تناول إحدى الجرعات، عليك أن تتناولها بمجرّد أن تتذكرها. على أي حال، إذا كان وقت تناول الجرعة التالية قد أصبح وشيكا، فلا تتناول الجرعة التي نسيتها؛ وعليك ببساطة أن تتابع تناول زمبلار حسب توجيهات طبيبك السابقة (من حيث الجرعة والوقت).&nbsp;</p><p>&nbsp;</p><p dir="RTL">لا تتناول جرعة مضاعفة للتعويض عن الجرعة التي نسيت تناولها.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول زمبلار</strong><strong> </strong></p><p dir="RTL">من المهم أن تستمر بتناول زمبلار حسب تعليمات طبيبك، إلا إذا أشار عليك طبيبك بإيقاف علاجك.</p><p>&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية بخصوص استعمال هذا الدواء، فاستشر طبيبك، أو الصيدلاني.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هي الحال مع كافة الأدوية، من الممكن أن يسبب هذا الدواء تأثيرات جانبية، رغم أنها لا تصيب كافة الأشخاص.</p><p>&nbsp;</p><p dir="RTL"><strong>هام: أخبر طبيبك على الفور إذا لاحظت حدوث أي من التأثيرات الجانبية التالي</strong><strong>ة:</strong></p><p>&nbsp;</p><p dir="RTL">شائعة (قد تصيب حتى ١ من ١٠ أشخاص): تشمل التأثيرات الجانبية التي شوهدت أثناء استعمال كبسولات باريكالسيتول ارتفاع المعدلات الدموية لمادة تدعى الكالسيوم، بالإضافة إلى حاصل كمية الكالسيوم x كمية مادة أخرى تدعى الفسفات (لدى المرضى المصابين بمرض كلوي مزمن واضح).</p><p>&nbsp;</p><p dir="RTL">غير شائعة (قد تصيب حتى ١ من ١٠٠ شخص): تشمل التأثيرات الجانبية التي شوهدت أثناء استعمال كبسولات باريكالسيتول تفاعلات تحسسية (مثل ضيق النفس، صفير الصدر، الطفح، الحكة، أو تورّم الوجه والشفتين)، تناقص معدلات هرمون الدُّريقات، إسهال، تشنجات عضلية، غثيان، دوخة، إنزعاج أو ألم المعدة، تقيؤ، ضغف، تعب، طفح، ذات الرئة، تناقص الشهية، ارتفاع معدلات الفسفور، تناقص معدلات الكالسيوم، طعم غير اعتيادي في الفم، ضربات قلب غير منتظمة، إمساك، جفاف الفم، حرقة المعدة (الرجع المعدي المريئي أو سوء الهضم)، العدّ (حب الشباب)، جلد حاكّ، شرى،&nbsp; ألم عضلي، مضض الثدي، الشعور بالتوعّك، تورم الساقين، ألم، ارتفاع معدلات الكرياتينين، وتغيرات في اختبارات الوظيفة الكبدية.</p><p><strong>&nbsp;</strong></p><p dir="RTL">اذا أصبت بتفاعل تحسسي، فاتصل بطبيبك على الفور.</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن التأثيرات الجانبية</strong></p><p dir="RTL">إذا أصبت بأي تأثير جانبي، تحدّث إلى طبيبك أو الصيدلاني. وهذا يشمل أي تأثيرات جانبية غير مدرجة في هذه النشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كما يمكنك الإبلاغ عن التأثيرات الجانبية مباشرة (انظر التفاصيل أدناه).</p><p>&nbsp;</p><p dir="RTL">بالإبلاغ عن التأثيرات الجانبية يمكنك أيضا المساعدة بتوفير مزيد من المعلومات عن سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">للإبلاغ عن أي تأثير(ات) جانبي(ـة):</p><p dir="RTL"><strong>المملكة العربية السعودية</strong></p><p dir="RTL">المركز الوطني للتيقظ والسلامة الدوائية&nbsp;</p><p dir="RTL">فاكس: +966-11-205-7662</p><p dir="RTL">اتصل بالمركز الوطني للتيقظ والسلامة الدوائية على</p><p dir="RTL">هاتف: +966-11-2038222</p><p dir="RTL">تحويلة: 2317 &ndash; 2356 &ndash; 2353 - 2354 -&nbsp; 2334 - 2340.</p><p dir="RTL">الهاتف المجاني: 8002490000</p><p dir="RTL">البريد الالكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الالكتروني: www.sfda.gov.sa/npc</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>بلدان مجلس التعاون الخليجي الأخرى:</strong></p><p dir="RTL">الرجاء الاتصال بالجهات المختصة المسؤولة.</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إحتفظ بهذا الدواء بعيدا عن مرأى الأطفال ومتناول أيديهم.</p><p>&nbsp;</p><p dir="RTL">احتفظ بكبسولات زمبلار ضمن درجة حرارة تعادل ٢٥ درجة مئوية (٧٧ درجة فهرنهايت).</p><p>&nbsp;</p><p dir="RTL">لا تستعمل هذا الدواء بعد انقضاء تاريخ الصلاحية المبيّن على الكرتونة وعلى اللصاقة بعد EXP. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المشار إليه.</p><p>&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية في مياه المجاري العامة أو مع قمامة المنزل. اسأل الصيدلاني عن طريقة التخلص من الأدوية التي لم تعد تستعملها. هذه الإجراءات تساعد على حماية البيئة.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><u>&nbsp;</u></p><p dir="RTL">المادة الفعالة هي باريكالسيتول. كل كبسولة طرية تحتوي على ٢ مكغ من باريكالسيتول.</p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: غليسيريدات ثلاثية متوطة السلسلة، إيثانول، بوتيل هيدروكسي التولوين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي غلاف الكبسولة على: جيلاتين، غليسيرول، ماء، ثاني أكسيد التيتانيوم إي ١٧١ (E171)، أكسيد الحديد الأحمر إي ١٧٢(E 172) وأكسيد الحديد الأصفر إي ١٧٢(E 172).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي حبر الطباعة على: بروبلين الغليكول، أكسيد الحديد الأسود إي ١٧٢(E 172)، بولي فنيل أسيتات فثالات، ماكروغول ٤٠٠، هيدروكسيد الأمونيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كبسولات زمبلار ٢ مكغ، هي كبسولات بيضاوية، برتقالية - بنية اللون، طرية مطبوع عليها &rsquo;ZF&lsquo;.</p><p>&nbsp;</p><p dir="RTL">تحتوي كل كرتونة إما على عبوة واحدة أو أربعة عبوات من نفاطات الألمنيوم. تحتوي كل عبوة على ٧ كبسولات.</p><p dir="RTL">قنينة البولي إيثيلين عالية الكثافة مع أغطية من البولي بروبلين مقاومة للطفل، تحتوي قنينة على 30 كبسولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">حامل رخصة التسويق:</p><p dir="RTL">آبفي ليمتد،</p><p>SL6 4UB ميدنهيد،</p><p dir="RTL">المملكة المتحدة</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL">الجهة المصنعة:</p><p dir="RTL">كاتالنت فارما سوليوشنز، إل إل سي، سانت بيترسبرغ، الولايات المتحدة</p><p>Catalent Pharma Solutions, LLC, St. Petersburg. USA</p><p dir="RTL">&nbsp;</p><p><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            	تمت آخر مراجعة لهذه النشرة في يونيو 2022.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zemplar 2 micrograms capsules, soft
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each capsule of Zemplar 2 microgram contains 2 microgram of paricalcitol.

Excipient with known effect:
Each capsule of Zemplar 2 microgram contains 1.42 mg of ethanol.

For a full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Capsule, soft

2 micrograms capsule:  oval, orange-brown soft capsule imprinted with ZF

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zemplar is indicated in adult patients for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal insufficiency (chronic kidney disease Stages 3 and 4) patients and chronic renal failure (chronic kidney disease Stage 5) who are on haemodialysis or peritoneal dialysis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p>Chronic Kidney Disease (CKD) Stages 3 and 4</p><p>&nbsp;</p><p>Zemplar should be administered once a day, either daily or three times a week taken every other day.</p><p>&nbsp;</p><p>Initial Dose</p><p>&nbsp;</p><p>The initial dose is based on baseline intact parathyroid hormone (iPTH) levels.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p>Table 1.&nbsp; Initial Dose</p><p>&nbsp;</p></td></tr><tr><td><p><strong>Baseline iPTH Level</strong></p></td><td><p><strong>Daily Dose</strong></p></td><td><p><strong>Three Times a Week Dose<sup>*</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>&le; 500 pg/mL (56 pmol/L)</p></td><td style="vertical-align:top"><p>1 microgram</p></td><td style="vertical-align:top"><p>2 micrograms</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 500 pg/mL (56 pmol/L)</p></td><td style="vertical-align:top"><p>2 micrograms</p></td><td style="vertical-align:top"><p>4 micrograms</p></td></tr><tr><td colspan="3" style="vertical-align:bottom"><p><sup>*</sup> To be administered no more frequently than every other day</p></td></tr></tbody></table><p>&nbsp;</p><p>Dose Titration</p><p>&nbsp;</p><p>Dosing must be individualised based on serum or plasma iPTH levels, with monitoring of serum calcium and serum phosphorus. Table 2 presents a suggested approach for dose titration.</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3"><p>Table 2.&nbsp; Dose Titration</p><p>&nbsp;</p></td></tr><tr><td rowspan="2"><p><strong>iPTH Level Relative to Baseline</strong></p></td><td colspan="2" style="vertical-align:bottom"><p>Dose Adjustment at 2 to 4 Week Intervals</p></td></tr><tr><td><p><strong>Daily Dose</strong></p></td><td><p><strong>Three Times a Week Dose<sup>1</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; The same or increased</p></td><td rowspan="2"><p>Increase</p><p>1 microgram</p></td><td rowspan="2"><p>Increase</p><p>2 micrograms</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Decreased by &lt; 30%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Decreased by &ge;30%, &nbsp;&nbsp;&nbsp; &le;60%</p></td><td><p>Maintain</p></td><td><p>Maintain</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Decreased &gt; 60%</p></td><td rowspan="2"><p>Decrease<sup>2</sup></p><p>1 microgram</p></td><td rowspan="2"><p>Decrease<sup>2</sup></p><p>2 micrograms</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; iPTH &lt; 60 pg/mL (7 pmol/L)</p></td></tr><tr><td colspan="3" style="vertical-align:bottom"><p><sup>1&nbsp;&nbsp;&nbsp;&nbsp; </sup>To be administered no more frequently than every other day.</p><p><sup>2</sup>&nbsp;&nbsp; If a patient is taking the lowest dose on the daily or three times a week regimen, and a dose reduction is needed, dosing frequency can be decreased.</p></td></tr></tbody></table><p>&nbsp;</p><p>Serum calcium levels should be closely monitored after initiation of the treatment and during dose titration periods. If hypercalcaemia or a persistently elevated calcium-phosphate product greater than &nbsp;55 mg<sup>2</sup>/dL<sup>2 </sup>(4.4 mmol<sup>2</sup> /L<sup>2</sup>) is observed, the dose of calcium based phosphate binders should be reduced or withheld. Alternatively, the dose of Zemplar may be reduced or temporarily interrupted. If interrupted, the drug should be restarted at a lower dose, when serum calcium and calcium-phosphorus product are in the target range.</p><p><em>&nbsp;</em></p><p>Chronic Kidney Disease (CKD), Stage 5</p><p>&nbsp;</p><p>Zemplar should be administered three times a week every other day.</p><p>&nbsp;</p><p>Initial Dose</p><p>&nbsp;</p><p>The initial dose of Zemplar in micrograms is based on a baseline iPTH level (pg/mL)/60 [(pmol/L)/7], up to an initial maximum dose of 32 micrograms.</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p>Dose Titration</p><p>&nbsp;</p><p>Subsequent dosing should be individualised and based on iPTH, serum calcium and phosphorus levels.&nbsp; A suggested dose titration of paricalcitol capsules is based on the following formula:</p><p>&nbsp;</p><p>Titration dose (micrograms) = <u>most recent iPTH level (pg/mL)</u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;60</p><p>OR</p><p>&nbsp;</p><p>Titration dose (micrograms) = <u>most recent iPTH level (pmol/L)</u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7</p><p>&nbsp;</p><p>Serum calcium and phosphorus levels should be closely monitored after initiation, during dose titration periods, and with co-administration of strong P450 3A inhibitors. If an elevated serum calcium or elevated Ca x P is observed and the patient is on a calcium-based phosphate binder, the binder dose may be decreased or withheld, or the patient may be switched to a non-calcium-based phosphate binder.&nbsp;</p><p>&nbsp;</p><p>If serum calcium &gt; 11.0 mg/dL (2.8 mmol/L) or Ca x P &gt; 70 mg<sup>2</sup>/dL<sup>2</sup> (5.6 mmol<sup>2</sup>/L<sup>2</sup>) or iPTH &pound; 150 pg/mL, the dose should be decreased by 2 to 4 micrograms with respect to that calculated by the most recent iPTH/60 (pg/mL) [iPTH/7 (pmol/L)]. If further adjustment is required, the dose of paricalcitol capsules should be reduced or interrupted until these parameters are normalised.</p><p>&nbsp;</p><p>As iPTH approaches the target range (150-300 pg/mL), small, individualised dose adjustments may be necessary in order to achieve a stable iPTH.&nbsp; In situations where monitoring of iPTH, Ca or P occurs less frequently than once per week, a more modest initial and dose titration ratio may be warranted.</p><p>&nbsp;</p><p>Special Populations</p><p>&nbsp;</p><p>Hepatic Impairment:</p><p>No dose adjustment is required in patients with mild to moderate hepatic impairment.</p><p>There is no experience in patients with severe hepatic impairment (see Section 5.2).</p><p>&nbsp;</p><p>Renal Transplant:</p><p>Post-renal transplant patients with CKD Stages 3 and 4 and secondary hyperparathyroidism were not studied in phase 3 clinical trials.&nbsp; Based on the published literature, the initial dose and dose-titration algorithm for patients with post-transplant CKD Stages 3 and 4 and secondary hyperparathyroidism is the same as for patients with native CKD Stages 3 and 4 and secondary hyperparathyroidism.&nbsp; Serum calcium and phosphorus levels should be closely monitored after initiation, during dose titration periods, and with co-administration of strong cytochrome P450 3A inhibitors.</p><p>&nbsp;</p><p>Paediatric population:</p><p>The safety and efficacy of Zemplar capsules in children under the age of 18 years have not yet been established.</p><p>Currently available data are described in section 5.1 but no recommendation on a posology can be made.</p><p>&nbsp;</p><p>Elderly:</p><p>No overall differences in safety and effectiveness were observed between elderly patients (65 &ndash; 75 years) with regard to younger patients, but greater sensitivity of some older individuals cannot be ruled out.&nbsp;</p><p>&nbsp;</p><p><u>Method of administration</u></p><p><u>&nbsp;</u></p><p>Zemplar can be taken with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Paricalcitol should not be given to patients with evidence of vitamin D toxicity, hypercalcaemia, or hypersensitivity to paricalcitol or any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Over suppression of parathyroid hormone may result in elevations of serum calcium levels and may lead to low-turnover bone disease. Patient monitoring and individualised dose titration is required to reach appropriate physiological endpoints.</p><p>&nbsp;</p><p>If clinically significant hypercalcaemia develops and the patient is receiving a calcium-based phosphate binder, the dose of the calcium-based phosphate binder should be reduced or interrupted.</p><p>&nbsp;</p><p>Chronic hypercalcaemia may be associated with generalised vascular calcification and other soft-tissue calcification.</p><p>&nbsp;</p><p>Phosphate or vitamin D-related medicinal products should not be taken concomitantly with</p><p>paricalcitol due to an increased risk of hypercalcaemia and Ca x P product elevation (see Section</p><p>4.5).</p><p>&nbsp;</p><p>Digitalis toxicity is potentiated by hypercalcaemia of any cause, so caution should be applied when digitalis is prescribed concomitantly with paricalcitol (see Section 4.5).</p><p><em>&nbsp;</em></p><p>In pre-dialysis patients, paricalcitol, like other vitamin D receptor activators, may increase</p><p>serum creatinine (and therefore decrease the estimated GFR [eGFR]) without changing true</p><p>glomerular filtration rate (GFR).</p><p>&nbsp;</p><p>Caution should be exercised if co-administering paricalcitol with ketoconazole (see Section 4.5).</p><p>&nbsp;</p><p>Warning for excipients:</p><p>&nbsp;</p><p>Each 2 microgram capsule contains 1.42 mg of alcohol (ethanol).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ketoconazole: Ketoconazole is known to be a nonspecific inhibitor of several cytochrome P450 enzymes.&nbsp; The available <em>in vivo</em> and <em>in vitro</em> data suggest that ketoconazole may interact with enzymes that are responsible for the metabolism of paricalcitol and other vitamin D analogues.&nbsp; Caution should be taken while dosing paricalcitol with ketoconazole.The effect of multiple doses of ketaconazole administered as 200 mg, twice daily (BID) for 5 days on the pharmacokinetics of paricalcitol capsule has been studied in healthy subjects. The Cmax of paricalcitol was minimally affected, but AUC0-&infin; approximately doubled in the presence of ketoconazole. The mean half-life of paricalcitol was 17.0 hours in the presence of ketoconazole as compared to 9.8 hours, when paricalcitol was administered alone (see Section 4.4).&nbsp; The results of this study indicate that following either oral or intravenous administration of paricalcitol the maximum amplification of the paricalcitol AUCINF from a drug interaction with ketoconazole is not likely to be greater than about two-fold.</p><p>&nbsp;</p><p>&nbsp;</p><p>Specific interaction studies were not performed.&nbsp; Digitalis toxicity is potentiated by hypercalcaemia of any cause, so caution should be applied when digitalis is prescribed concomitantly with paricalcitol.</p><p><strong>&nbsp;</strong></p><p>Phosphate or vitamin D-related medicinal products should not be taken concomitantly with paricalcitol due to an increased risk of hypercalcaemia and Ca x P product elevation (see Section 4.4).</p><p>&nbsp;</p><p>High doses of calcium-containing preparation or thiazide diuretics may increase the risk of hypercalcaemia.</p><p>&nbsp;</p><p>Magnesium-containing preparations (e.g. antacids) should not be taken concomitantly with vitamin D preparations, because hypermagnesemia may occur.</p><p>&nbsp;</p><p>Aluminium-containing preparations (e.g. antacids, phosphate-binders) should not be administered chronically with Vitamin D medicinal products, as increased blood levels of aluminium and aluminium bone toxicity may occur.</p><p>&nbsp;</p><p>Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of Zemplar capsules.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>There is no adequate data on the use of paricalcitol in pregnant women. Animal studies have shown reproductive toxicity (see section 5.3). Potential risk in human use is not known, therefore paricalcitol should not be used unless clearly necessary.</p><p>&nbsp;</p><p><strong>Breastfeeding</strong></p><p>It is not known whether paricalcitol is excreted in human milk. <em>&nbsp;</em>Animal studies have shown excretion of paricalcitol or its metabolites in breast milk, in small amounts.&nbsp; A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Zemplar should be made taking into account the benefit of breast-feeding to the child and the benefit of Zemplar therapy to the woman.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zemplar has negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The safety of paricalcitol capsules has been evaluated in three 24-week, double-blind, placebo-controlled, multi-centre clinical trials involving 220 CKD Stage 3 and 4 patients and in one 12-week, double-blind, placebo-controlled, multi-centre clinical trial involving 88&nbsp;CKD Stage 5 patients. In addition, there is postmarketing experience with paricalcitol capsules from two additional studies. The most commonly reported adverse reactions for paricalcitol treated patients were hypercalcaemia and calcium phosphate product increased.</p><p>In the Stage 3/4 and Stage 5 clinical trials, the incidence of hypercalcaemia was Zemplar (3/167, 2%) vs placebo (0/137, 0%) and elevated calcium phosphate product was Zemplar (19/167, 11%) vs placebo (8/137, 6%).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>All adverse reactions associated with Zemplar Capsules are displayed in Table 3 by MedDRA System Organ Class, Preferred Term and frequency. The following frequency groupings are used: very common (&sup3;1/10); common (&sup3;1/100 to &lt;1/10); uncommon (&sup3;1/1,000 to &lt;1/100); rare (&sup3;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), unknown (cannot be estimated from the available data).</p><p>&nbsp;</p><p><strong>Table 3: Adverse Reactions Reported With Zemplar Capsules in Clinical Trials and From Post Marketing Experience</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:594px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong><sup>*</sup></p></td><td style="vertical-align:top"><p><strong>Adverse Reaction</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Pneumonia</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td></tr><tr><td style="vertical-align:top"><p>Unknown</p></td><td style="vertical-align:top"><p>Angioedema, laryngeal oedema</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine Disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hypoparathyroidism</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypercalcaemia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Decreased appetite, hyperphosphataemia, hypocalcaemia</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Dizziness, dysgeusia</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Palpitations</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Abdominal discomfort, abdominal pain upper, constipation, diarrhoea, dry mouth, gastroesophageal reflux disease, nausea, vomiting</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Acne, pruritus, rash, urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Muscle spasms, myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Breast tenderness</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Asthenia, malaise, oedema peripheral, pain</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Calcium phosphate product increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Blood creatinine increased<sup>&dagger;</sup>, hepatic enzyme abnormal</p></td></tr></tbody></table><p>&nbsp;</p><p><sup>*</sup>Frequencies for adverse reactions from postmarketing experience cannot be estimated and have been reported as &ldquo;Unknown.&rdquo;<br /><sup>&dagger;</sup>This adverse reaction has been observed in studies in predialysis patients (see also section 4.4).</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: +966-11-205-7662</p><p>Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>Toll free phone: 8002490000</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p><p><strong>&nbsp;</strong></p><p><strong>Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Excessive administration of Zemplar capsules can cause hypercalcaemia, hypercalciuria, hyperphosphataemia, and over suppression of parathyroid hormone. High intake of calcium and phosphate concomitant with Zemplar capsules may lead to similar abnormalities.</p><p>&nbsp;</p><p>Treatment of patients with clinically significant hypercalcaemia consists of immediate dose reduction or interruption of paricalcitol therapy and includes a low calcium diet, withdrawal of calcium supplements, patient mobilisation, attention to fluid and electrolyte imbalances, assessment of electrocardiographic abnormalities (critical in patients receiving digitalis), and haemodialysis or peritoneal dialysis against a calcium-free dialysate, as warranted.</p><p>&nbsp;</p><p>Signs and symptoms of vitamin D intoxication associated with hypercalcaemia include:</p><p>&nbsp;</p><p>Early:&nbsp; Weakness, headache, somnolence, nausea, vomiting, dry mouth, constipation, muscle pain, bone pain and metallic taste.</p><p>&nbsp;</p><p>Late:&nbsp; Anorexia, weight loss, conjunctivitis (calcific), pancreatitis, photophobia, rhinorrhoea, pruritis, hyperthermia, decreased libido, elevated BUN, hypercholesterolaemia, elevated AST and ALT, ectopic calcification, hypertension, cardiac arrhythmias, somnolence, death and rarely, overt psychosis.</p><p>&nbsp;</p><p>Serum calcium levels should be monitored frequently until normocalcaemia ensues.</p><p>Paricalcitol is not significantly removed by dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Anti-parathyroid agents &ndash;ATC code: H05BX02.</p><p><em>&nbsp;</em></p><p>Mechanism of Action</p><p>&nbsp;</p><p>Paricalcitol is a synthetic, biologically active vitamin D analog of calcitriol with modifications to the side chain (D<sub>2</sub>) and the A (19-nor) ring. Unlike calcitriol, paricalcitol is a selective vitamin D receptor (VDR) activator. Paricalcitol selectively upregulates the VDR in the parathyroid glands without increasing VDR in the intestine and is less active on bone resorption. Paricalcitol also upregulates the calcium sensing receptor in the parathyroid glands.&nbsp; As a result, paricalcitol reduces parathyroid hormone (PTH) levels by inhibiting parathyroid proliferation and decreasing PTH synthesis and secretion, with minimal impact on calcium and phosphorus levels, and can act directly on bone cells to maintain bone volume and improve mineralization surfaces. Correcting abnormal PTH levels, with normalisation of calcium and phosphorus homeostasis, may prevent or treat the metabolic bone disease associated with chronic kidney disease.</p><p>&nbsp;</p><p>Clinical Efficacy</p><p>&nbsp;</p><p>Chronic Kidney Disease, Stages 3-4</p><p>&nbsp;</p><p>The primary efficacy endpoint of at least two consecutive &sup3; 30 % reductions from baseline iPTH was achieved by 91% of paricalcitol capsules-treated patients and 13% of the placebo patients (p&lt;0.001).&nbsp; Serum bone specific alkaline phosphatase like serum osteocalcin were significantly reduced (p&lt;0.001) in patients treated with paricalcitol capsules compared to placebo, which is associated with a correction of the high bone turnover due to secondary hyperparathyroidism. No deterioration in the kidney function parameters of estimated glomerular filtration rate (via MDRD formula) and serum creatinine was detected in paricalcitol capsules treated patients in comparison to placebo treated patients. Significantly more of paricalcitol capsules treated patients experienced a reduction in urinary protein, as measured by semiquantitative dipstick, compared to placebo treated patients.</p><p>&nbsp;</p><p>Chronic kidney disease, Stage 5</p><p>&nbsp;</p><p>The primary efficacy endpoint of at least two consecutive &sup3; 30 % reductions from baseline iPTH was achieved by 88% of paricalcitol capsules treated patients and 13% of the placebo patients (p&nbsp;&lt;&nbsp;0.001).</p><p>&nbsp;</p><p>Paediatric clinical data with Zemplar Injection (IV)</p><p>The safety and effectiveness of Zemplar IV were examined in a 12-week randomised, double-blind, placebo-controlled study of 29 pediatric patients, aged 5-19 years, with end-stage renal disease on hemodialysis. The six youngest Zemplar IV-treated patients in the study were 5 - 12 years old. The initial dose of Zemplar IV was 0.04 mcg/kg 3 times per week, based on baseline iPTH level of less than 500 pg/mL, or 0.08 mcg/kg 3 times a week based on baseline iPTH level of &ge; 500 pg/mL, respectively. The dose of Zemplar IV was adjusted in 0.04 mcg/kg increments based on the levels of serum iPTH, calcium, and Ca x P. 67% of the Zemplar IV-treated patients and 14% placebo-treated patients completed the trial. 60% of the subjects in the Zemplar IV group had 2 consecutive 30% decreases from baseline iPTH compared with 21% patients in the placebo group. 71% of the placebo patients were discontinued due to excessive elevations in iPTH levels. No subjects in either the Zemplar IV group or placebo group developed hypercalcaemia. No data are available for patients under the age of 5.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption</p><p>&nbsp;</p><p>Paricalcitol is well absorbed. In healthy subjects, following oral administration of paricalcitol at 0.24&nbsp;micrograms/kg, the mean absolute bioavailability was approximately 72%; the maximum plasma concentration (C<sub>max</sub>) was 0.630 ng/mL (1.512 pmol/mL) at 3 hours and area under the concentration time curve (AUC<sub>0-</sub><sub>&yen;</sub>) was 5.25 ng&middot;h/mL (12.60 pmol&bull;h/mL). The mean absolute bioavailability of paricalcitol in hemodialysis (HD) and peritoneal dialysis (PD) patients is 79% and 86%, respectively, with the upper bound of 95% confidence interval of 93% and 112%, respectively.&nbsp; &nbsp;A food interaction study in healthy subjects indicated that the C<sub>max</sub> and AUC<sub>0-&infin;</sub> were unchanged when paricalcitol was administered with a high fat meal compared to fasting. Therefore, Zemplar capsules may be taken without regard to food.</p><p>&nbsp;</p><p>The C<sub>max</sub> and AUC<sub>0-&infin;</sub> of paricalcitol increased proportionally over the dose range of 0.06 to 0.48 micrograms/kg in healthy subjects. Following multiple dosing, either as daily or three times a week in healthy subjects, steady-state exposure was reached within seven days.</p><p>&nbsp;</p><p>&nbsp;</p><p>Distribution</p><p>&nbsp;</p><p>Paricalcitol is extensively bound to plasma proteins (&gt;&nbsp;99%). The ratio of blood paricalcitol to plasma paricalcitol concentration averaged 0.54 over the concentration range of 0.01 to 10&nbsp;ng/mL (0.024 to 24 pmol/mL) indicating that very little drug associated with blood cells. The mean apparent volume of distribution following a 0.24 micrograms/kg dose of paricalcitol in healthy subjects was 34 litres.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Biotransformation</strong></p><p>&nbsp;</p><p>After oral administration of a 0.48 micrograms/kg dose of <sup>3</sup>H-paricalcitol, parent drug was extensively metabolised, with only about 2% of the dose eliminated unchanged in the faeces, and no parent drug found in the urine. Approximately 70% of the radioactivity was eliminated in the faeces and 18% was recovered in the urine. Most of the systemic exposure was from the parent drug. Two minor metabolites, relative to paricalcitol, were detected in human plasma. One metabolite was identified as 24(R)-hydroxy paricalcitol, while the other metabolite was unidentified. The 24(R)-hydroxy paricalcitol is less active than paricalcitol in an <em>in vivo</em> rat model of PTH suppression.</p><p><em>&nbsp;</em></p><p><em>In vitro</em> data suggest that paricalcitol is metabolised by multiple hepatic and non-hepatic enzymes, including mitochondrial CYP24, as well as CYP3A4 and UGT1A4. The identified metabolites include the product of 24(R)-hydroxylation, as well as 24,26- and 24,28-dihydroxylation and direct glucuronidation.</p><p>&nbsp;</p><p>Elimination</p><p><strong>&nbsp;</strong></p><p>In healthy subjects, the mean elimination half-life of paricalcitol is five to seven hours over the studied dose range of 0.06 to 0.48 micrograms/kg. The degree of accumulation was consistent with the half-life and dosing frequency. Haemodialysis procedure has essentially no effect on paricalcitol elimination.</p><p>&nbsp;</p><p>Special Populations</p><p>&nbsp;</p><p>Elderly</p><p>&nbsp;</p><p>The pharmacokinetics of paricalcitol have not been investigated in patients greater than 65 years.</p><p>&nbsp;</p><p>Paediatric</p><p>&nbsp;</p><p>The pharmacokinetics of paricalcitol have not been investigated in patients less than 18 years of age.</p><p>&nbsp;</p><p>Gender</p><p>&nbsp;</p><p>The pharmacokinetics of paricalcitol following single doses over 0.06 to 0.48 micrograms/kg dose range were gender independent.</p><p>&nbsp;</p><p><u>Hepatic Impairment</u></p><p>&nbsp;</p><p>In a study performed with Zemplar intravenous, the disposition of paricalcitol (0.24 micrograms/kg) was compared in patients with mild (n = 5) and moderate (n = 5) hepatic impairment (in accordance with the Child-Pugh method) and subjects with normal hepatic function (n = 10). The pharmacokinetics of unbound paricalcitol was similar across the range of hepatic function evaluated in this study. No dosing adjustment is required in patients with mild to moderate hepatic impairment. The influence of severe hepatic impairment on the pharmacokinetics of paricalcitol has not been evaluated.</p><p>&nbsp;</p><p>Renal Impairment</p><p>&nbsp;</p><p>Paricalcitol pharmacokinetics following single dose administration were characterised in patients with CKD Stage 3 or moderate renal impairment (n = 15, GFR = 36.9 to 59.1 mL/min/1.73 m<sup>2</sup>), CKD Stage 4 or severe renal impairment (n&nbsp; = 14, GFR = 13.1 to 29.4 mL/min/1.73 m<sup>2</sup>), and CKD 5 or end-stage renal disease [n = 14 in haemodialysis (HD) and n = 8 in peritoneal dialysis (PD)]. Similar to endogenous 1,25(OH)<sub>2</sub> D<sub>3</sub>, the pharmacokinetics of paricalcitol following oral administration were affected significantly by renal impairment, as shown in Table 4. Compared to healthy subjects results obtained, Chronic Kidney Disease, Stage 3, 4, and 5 patients showed decreased CL/F and increased half-life.</p><p>&nbsp;</p><p>Table&nbsp;4. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Comparison of Mean &plusmn; SD Pharmacokinetic Parameters in Different Stages of Renal Impairment <em>versus</em> Healthy Subjects</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>Pharmacokinetic Parameter</strong></p></td><td rowspan="2"><p><strong>Healthy Subjects</strong></p></td><td rowspan="2"><p><strong>CKD Stage 3</strong></p></td><td rowspan="2"><p><strong>CKD Stage 4</strong></p></td><td colspan="2"><p><strong>CKD Stage 5</strong></p></td></tr><tr><td><p><strong>HD</strong></p></td><td><p><strong>PD</strong></p></td></tr><tr><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>Dose (micrograms/kg)</p></td><td style="vertical-align:top"><p>0.240</p></td><td style="vertical-align:top"><p>0.047</p></td><td style="vertical-align:top"><p>0.036</p></td><td style="vertical-align:top"><p>0.240</p></td><td style="vertical-align:top"><p>0.240</p></td></tr><tr><td style="vertical-align:top"><p>CL/F (L/h)</p></td><td style="vertical-align:top"><p>3.6 &plusmn; 1.0</p></td><td style="vertical-align:top"><p>1.8 &plusmn; 0.5</p></td><td style="vertical-align:top"><p>1.5 &plusmn; 0.4</p></td><td style="vertical-align:top"><p>1.8 &plusmn; 0.8</p></td><td style="vertical-align:top"><p>1.8 &plusmn; 0.8</p></td></tr><tr><td style="vertical-align:top"><p>t<sub>&frac12;</sub>(h)</p></td><td style="vertical-align:top"><p>5.9 &plusmn; 2.8</p></td><td style="vertical-align:top"><p>16.8 &plusmn; 2.6</p></td><td style="vertical-align:top"><p>19.7 &plusmn; 7.2</p></td><td style="vertical-align:top"><p>13.9 &plusmn; 5.1</p></td><td style="vertical-align:top"><p>17.7 &plusmn; 9.6</p></td></tr><tr><td style="vertical-align:top"><p>f<sub>u</sub><sup>*</sup> (%)</p></td><td style="vertical-align:top"><p>0.06 &plusmn; 0.01</p></td><td style="vertical-align:top"><p>0.06 &plusmn; 0.01</p></td><td style="vertical-align:top"><p>0.07 &plusmn; 0.02</p></td><td style="vertical-align:top"><p>0.09 &plusmn; 0.04</p></td><td style="vertical-align:top"><p>0.13 &plusmn; 0.08</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>* Measured at 15 nM paricalcitol concentration.</p></td></tr></tbody></table><p>&nbsp;</p><p>Following oral administration of paricalcitol capsules, the pharmacokinetic profile of paricalcitol for chronic kidney disease, Stages 3 to 5 was comparable. Therefore, no special dosing adjustments are required other than those recommended (see section 4.2).</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Salient findings in the repeat-dose toxicology studies in rodents and dogs were generally attributed to paricalcitol&rsquo;s calcaemic activity. Effects not clearly related to hypercalcaemia included decreased white blood cell counts and thymic atrophy in dogs, and altered APTT values (increased in dogs, decreased in rats).&nbsp;&nbsp; WBC changes were not observed in clinical trials of paricalcitol.</p><p>&nbsp;</p><p>Paricalcitol did not affect fertility in rats and there was no evidence of teratogenic activity in rats or rabbits. High doses of other vitamin D preparations applied during pregnancy in animals lead to teratogenesis. Paricalcitol was shown to affect fetal viability, as well as to promote a significant increase of peri-natal and post-natal mortality of newborn rats, when administered at maternally toxic doses.</p><p>&nbsp;</p><p>Paricalcitol did not exhibit genotoxic potential in a set of <em>in-vitro </em>and <em>in-vivo </em>genotoxicity assays.</p><p>&nbsp;</p><p>Carcinogenicity studies in rodents did not indicate any special risks for human use.</p><p>&nbsp;</p><p>Doses administered and/or systemic exposures to paricalcitol were slightly higher than therapeutic doses/systemic exposures.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Capsule contents:</u></p><p>Medium chain triglycerides</p><p>Ethanol</p><p>Butylhydroxytoluene</p><p>&nbsp;</p><p><u>Capsule shell:</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Gelatin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Glycerol&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Water&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Titanium dioxide (E171)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Iron oxide red (E172)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Iron oxide yellow (E172)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><u>Black Ink:</u></p><p>Propylene glycol</p><p>Black iron oxide (E172)</p><p>Polyvinyl acetate phthalate</p><p>Macrogol 400</p><p>Ammonium hydroxide</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store ZEMPLAR Capsules below&nbsp; 25&deg;C (77&deg;F)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>High-density polyethylene (HDPE) bottles closed with child-resistant polypropylene caps.&nbsp; Each bottle contains 30 capsules.</p><p>&nbsp;</p><p>PVC/fluoropolymer/aluminium blister strips containing 7 capsules. Each carton contains 1 or 4 blister strips.&nbsp; Packaged in outer cartons containing either 7 or 28 capsules.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AbbVie Ltd. 
Maidenhead
SL6 4UB
United Kingdom 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                June 2022 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>